{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Xu Y"],"pubmed_abstract":["<h4>Introduction</h4>This study assessed the safety and efficacy of B cell- and anti-PLA2R antibody-targeted low-dose rituximab therapy in patients with idiopathic membranous nephropathy (IMN).<h4>Methods</h4>This was a multicenter, investigator-initiated, open-label, prospective cohort study. Patients were recruited from 10 hospitals in the east coastal region of China between November 1<sup>st</sup>, 2019 and June 15<sup>th</sup>, 2023. Enrolled patients were assigned to individualized rituximab therapy (guided by peripheral B cells and anti-PLA2R antibody levels) or standard rituximab therapy (1,000 mg × 2 or 375 mg/m² × 3-4): the individualized group (n = 78) and the standard group (n = 62). Odds ratios (ORs) and 95% confidence intervals (CIs) for response were estimated using multivar"],"journal":["Frontiers in immunology"],"pagination":["1633532"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12484018"],"repository":["biostudies-literature"],"pubmed_title":["B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China."],"pmcid":["PMC12484018"],"pubmed_authors":["Shen L","Liu J","Sun B","Xing C","Mao H","Zhang L","Wang L","Liu X","Wan C","Bi G","Wang N","Bian S","Sun D","Zhou G","Zhang C","Zhang B","Zhou H","Yuan Y","Yang M","Chen L","Zeng M","Lu F","Lu G","Zhang X","Jiang C","Liu C","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.","description":"<h4>Introduction</h4>This study assessed the safety and efficacy of B cell- and anti-PLA2R antibody-targeted low-dose rituximab therapy in patients with idiopathic membranous nephropathy (IMN).<h4>Methods</h4>This was a multicenter, investigator-initiated, open-label, prospective cohort study. Patients were recruited from 10 hospitals in the east coastal region of China between November 1<sup>st</sup>, 2019 and June 15<sup>th</sup>, 2023. Enrolled patients were assigned to individualized rituximab therapy (guided by peripheral B cells and anti-PLA2R antibody levels) or standard rituximab therapy (1,000 mg × 2 or 375 mg/m² × 3-4): the individualized group (n = 78) and the standard group (n = 62). Odds ratios (ORs) and 95% confidence intervals (CIs) for response were estimated using multivar","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-04T02:30:21.194Z","creation":"2026-05-04T03:13:46.564Z"},"accession":"S-EPMC12484018","cross_references":{"pubmed":["41041325"],"doi":["10.3389/fimmu.2025.1633532"]}}